Miriam Ramirez

Ms. Miriam Ramirez

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ECElisabet Marti Coma-Cros
Elisabet Marti Coma-Cros
ARArnau Biosca Romanillos
Arnau Biosca Romanillos
ELElena Lantero
Elena Lantero
Maria Letizia MancaMaria Letizia Manca
Maria Letizia Manca
CCCarla Caddeo
Carla Caddeo
Xavier Fernàndez-BusquetsXavier Fernàndez-Busquets
Xavier Fernàndez-Busquets
Curcumin is an antimalarial compound easy to obtain and inexpensive, having shown little toxicity across a diverse population. However, the clinical use of this interesting polyphenol has been hampered by its poor oral absorption, extremely low aqueous solubility and rapid metabolism. In this study, we have used the anionic copolymer Eudragit® S100 to assemble liposomes incorporating curcumin and containing either hyaluronan (Eudragit-hyaluronan liposomes) or the water-soluble dextrin Nutriose® FM06 (Eudragit-nutriosomes). Upon oral administration of the rehydrated freeze-dried nanosystems administered at 25/75 mg curcumin·kg−1·day−1, only Eudragit-nutriosomes improved the in vivo antimalarial activity of curcumin in a dose-dependent manner, by enhancing the survival of all Plasmodium yoelii-infected mice up to 11/11 days, as compared to 6/7 days upon administration of an equal dose of the free compound. On the other hand, animals treated with curcumin incorporated in Eudragit-hyaluronan liposomes did not live longer than the controls, a result consistent with the lower stability of this formulation after reconstitution. Polymer-lipid nanovesicles hold promise for their development into systems for the oral delivery of curcumin-based antimalarial therapies.

21 May 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MBMaria Carmen Fernandez Becerra
Maria Carmen Fernandez Becerra
MBMaria Bernabeu
Maria Bernabeu
ACAngélica Castellanos
Angélica Castellanos
BCBruna R. Correa
Bruna R. Correa
TOThomas Obadia
Thomas Obadia
HPHernando Del Portillo
Hernando Del Portillo
Plasmodium vivax, the most widely distributed human malaria parasite, causes severe clinical syndromes despite low peripheral blood parasitemia. This conundrum is further complicated as cytoadherence in the microvasculature is still a matter of investigations. Previous reports inPlasmodium knowlesi, another parasite species shown to infect humans, demonstrated that variant genes involved in cytoadherence were dependent on the spleen for their expression. Hence, using a global transcriptional analysis of parasites obtained from spleen-intact and splenectomized monkeys, we identified 67P. vivaxgenes whose expression was spleen dependent. To determine their role in cytoadherence, twoPlasmodium falciparumtransgenic lines expressing two variant proteins pertaining to VIR and Pv-FAM-D multigene families were used. Cytoadherence assays demonstrated specific binding to human spleen but not lung fibroblasts of the transgenic line expressing the VIR14 protein. To gain more insights, we expressed fiveP. vivaxspleen-dependent genes as recombinant proteins, including members of three different multigene families (VIR, Pv-FAM-A, Pv-FAM-D), one membrane transporter (SECY), and one hypothetical protein (HYP1), and determined their immunogenicity and association with clinical protection in a prospective study of 383 children in Papua New Guinea. Results demonstrated that spleen-dependent antigens are immunogenic in natural infections and that antibodies to HYP1 are associated with clinical protection. These results suggest that the spleen plays a major role in expression of parasite proteins involved in cytoadherence and can reveal antigens associated with clinical protection, thus prompting a paradigm shift inP. vivaxbiology toward deeper studies of the spleen during infections.

22 September 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
VLVirginio Cepas Lopez
Virginio Cepas Lopez
VTVictoria Ballén Torres
Victoria Ballén Torres
YGYaiza Gabasa
Yaiza Gabasa
MRMiriam Ramirez
Miriam Ramirez
YLYuly Lopez
Yuly Lopez
Sara GonzálezSara González
Sara González
Current Escherichia coli antibiofilm treatments comprise a combination of antibiotics commonly used against planktonic cells, leading to treatment failure. A better understanding of the genes involved in biofilm formation could facilitate the development of efficient and specific new antibiofilm treatments. A total of 2578 E. coli mutants were generated by transposon insertion, of which 536 were analysed in this study. After sequencing, Tn263 mutant, classified as low biofilm-former (LF) compared to the wild-type (wt) strain (ATCC 25922), showed an interruption in the purL gene, involved in the de novo purine biosynthesis pathway. To elucidate the role of purL in biofilm formation, a knockout was generated showing reduced production of curli fibres, leading to an impaired biofilm formation. These conditions were restored by complementation of the strain or addition of exogenous inosine. Proteomic and transcriptional analyses were performed to characterise the differences caused by purL alterations. Thirteen proteins were altered compared to wt. The corresponding genes were analysed by qRT-PCR not only in the Tn263 and wt, but also in clinical strains with different biofilm activity. Overall, this study suggests that purL is essential for biofilm formation in E. coli and can be considered as a potential antibiofilm target.

1 April 2021 in Analytica Chimica Acta
Verified
Journal Article
Closed access
ESErica de la Serna
Erica de la Serna
KAKevin Arias-Alpizar
Kevin Arias-Alpizar
Livia Neves Borgheti-CardosoLivia Neves Borgheti-Cardoso
Livia Neves Borgheti-Cardoso
ASAna Sanchez-Cano
Ana Sanchez-Cano
ESElena Sulleiro
Elena Sulleiro
EBEva Baldrich
Eva Baldrich

19 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CMCARLOTA ROCA MARTINEZ
CARLOTA ROCA MARTINEZ
YAYunuen Avalos-Padilla
Yunuen Avalos-Padilla
Beatriz Prieto-SimónBeatriz Prieto-Simón
Beatriz Prieto-Simón
VIValentín Iglesias
Valentín Iglesias
MRMiriam Ramirez
Miriam Ramirez
Xavier Fernàndez-BusquetsXavier Fernàndez-Busquets
Xavier Fernàndez-Busquets
The methyl erythritol phosphate (MEP) pathway of isoprenoid biosynthesis is essential for malaria parasites and also for several human pathogenic bacteria, thus representing an interesting target for future antimalarials and antibiotics and for diagnostic strategies. We have developed a DNA aptamer (D10) against Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), the second enzyme of this metabolic route. D10 binds in vitro to recombinant DXR from P. falciparum and Escherichia coli, showing at 10 µM a ca. 50% inhibition of the bacterial enzyme. In silico docking analysis indicates that D10 associates with DXR in solvent-exposed regions outside the active center pocket. According to fluorescence confocal microscopy data, this aptamer specifically targets in P. falciparum in vitro cultures the apicoplast organelle where the MEP pathway is localized and is, therefore, a highly specific marker of red blood cells parasitized by Plasmodium vs. naïve erythrocytes. D10 is also selective for the detection of MEP+ bacteria (e.g., E. coli and Pseudomonas aeruginosa) vs. those lacking DXR (e.g., Enterococcus faecalis). Based on these results, we discuss the potential of DNA aptamers in the development of ligands that can outcompete the performance of the well-established antibody technology for future therapeutic and diagnostic approaches.

22 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ARArnau Biosca Romanillos
Arnau Biosca Romanillos
MRMiriam Ramirez
Miriam Ramirez
AGAlex Gomez-Gomez
Alex Gomez-Gomez
ALAritz Lafuente
Aritz Lafuente
VIValentín Iglesias
Valentín Iglesias
Xavier Fernàndez-BusquetsXavier Fernàndez-Busquets
Xavier Fernàndez-Busquets
The evolution of resistance by the malaria parasite to artemisinin, the key component of the combination therapy strategies that are at the core of current antimalarial treatments, calls for the urgent identification of new fast-acting antimalarials. The apicoplast organelle is a preferred target of antimalarial drugs because it contains biochemical processes absent from the human host. Fosmidomycin is the only drug in clinical trials targeting the apicoplast, where it inhibits the methyl erythritol phosphate (MEP) pathway. Here, we characterized the antiplasmodial activity of domiphen bromide (DB), another MEP pathway inhibitor with a rapid mode of action that arrests the in vitro growth of Plasmodium falciparum at the early trophozoite stage. Metabolomic analysis of the MEP pathway and Krebs cycle intermediates in 20 µM DB-treated parasites suggested a rapid activation of glycolysis with a concomitant decrease in mitochondrial activity, consistent with a rapid killing of the pathogen. These results present DB as a model compound for the development of new, potentially interesting drugs for future antimalarial combination therapies.